PA
TPVG icon

PharVision Advisers’s TriplePoint Venture Growth BDC TPVG Stock Holding History

PharVision Advisers’s Portfolio TPVG Stock Details TPVG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,193
Closed -$92.1K – 431
2025
Q1 		$92.1K Buy
13,193
+1,789
+16% +$13.7K 0.13% 252
2024
Q4 		$84.2K Buy
+11,404
New +$83.9K 0.07% 376

Other funds holding TPVG

Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
VIA
Virtus Investment Advisers Hartford, Connecticut $363M AUM 34.89% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
SIC
Samalin Investment Counsel Chappaqua, New York $282M AUM 16.72% 1-Year Est. Return
TI
Trexquant Investment Stamford, Connecticut $13.9B AUM 31.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PharVision Advisers's TPVG Position: Q2 2025 in Review

PharVision Advisers sold out of TriplePoint Venture Growth BDC (TPVG) in Q2 2025, closing a stake of 13,193 shares — an estimated $92.1K sold.

PharVision Advisers first reported a position in TPVG in Q4 2024 and held it in 2 quarters. The position peaked at $92.1K in Q1 2025. 66 funds tracked by Wall St. Rank hold TPVG as of Q2 2025.

  • PharVision Advisers reported no remaining TriplePoint Venture Growth BDC position as of Q2 2025 after selling out during the quarter.
  • PharVision Advisers sold 13,193 TriplePoint Venture Growth BDC shares in Q2 2025, an estimated $92.1K.
  • PharVision Advisers first reported a position in TriplePoint Venture Growth BDC in Q4 2024 and held it in 2 quarters.
  • PharVision Advisers's TriplePoint Venture Growth BDC position peaked at $92.1K in Q1 2025.
  • 66 funds tracked by Wall St. Rank held TriplePoint Venture Growth BDC as of Q2 2025.

Based on PharVision Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.